New Agents, New Regimens, New Strategies

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.

Advertisements

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-1 Phase 3 Treatment Naïve Source: Afdhal N, et al. N.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Phase 2 Treatment.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.

Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase 2a, Treatment Naïve and Treatment Experienced.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in Treatment-Experienced GT1 with Cirrhosis SIRIUS Phase 2 Treatment Experienced Bourliere.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in Sofosbuvir-Experienced HCV GT1 Retreatment of Sofosbuvir Failures Phase 2 Treatment.

Module 6: Treatment options. Module goal To enable participants understand the best current treatment options, factors that influence outcomes and potential.

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

ALLY-1  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml) in genotype 1 DCV 60 mg qd + SOF 400 mg qd + RBV DCV 60 mg qd + SOF 400 mg qd + RBV Not randomised.

Roth D. EASL 2015, Abs. LP02 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR + EBR (Intensive.

Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 5 or 6 Robert G. Gish MD Staff Physician, Stanford University.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Phase 2 Treatment.

SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.

ION-4  Design LDV/SOF Open-label ION-4 Study: LDV/SOF in HIV co-infection W12 ≥ 18 years Chronic HCV infection Genotype 1 or 4 HCV RNA ≥ 10,000 IU/ml.

SOLAR-1 LDV/SOF + RBV Randomisation* of the 7 groups 1 : 1 Open-label SOLAR-1 Study: LDV/SOF + RBV in advanced liver disease  Design W12W24 ≥ 18 years.

FDA Hepatitis C Hearing Oct 19, 2006 Jules Levin Executive Director/Founder, NATAP National AIDS Treatment Advocacy Project.

> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.

Forns X. J Hepatology 2015; 63: C-SALVAGE Study: grazoprevir + elbasvir + RBV in genotype 1 with failure to PI-based regimen –NS3 and NS5A RAVs.

Sulkowski M. Lancet 2015;385: C-WORTHY  Design Randomisation* Open-label > 18 years HCV genotype 1, treatment naïve HCV RNA ≥ 10,000 IU/ml No cirrhosis.

Roth D. Lancet 2015; Oct 6; 386: C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR.

Open-label W24 ≥ 18 years Chronic HCV infection All genotypes HCV RNA ≥ 10,000 IU/ml Liver transplantation months earlier Child Pugh ≤ 7 and MELD.

LDV/SOF Failure Open-label W24 Chronic HCV infection Genotype 1 Failure to achieve SVR on LDV/SOF-containing regimen Compensated cirrhosis (liver biopsy.

LDV/SOF Open-label Chronic HCV infection Genotype 1 Failure to achieve SVR 12 on a short-course of 1 st line LDV/SOF-containing regimen No cirrhosis N.

Phase 3 Treatment Experienced

Where Are We on the Path to Elimination of Chronic Hepatitis C?

Interim Analysis of a 3-Year Follow-up Study of NS5A and NS3 Resistance-Associated Variants After Treatment With Grazoprevir-Containing Regimens in Patients.

EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.

Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis

Elbasvir-Grazoprevir (Zepatier)

Design Randomisation 1 : 1 Open-label W16 W24 > 18 years

Phase 3 Treatment-Naïve and Treatment-Experienced

Interactive Workshop.

Retreatment study: SOF/VEL + RBV in prior NS5A failure - Phase II

Phase 3b Treatment-Naive

Phase 3 Treatment-Naïve and Treatment-Experienced

Initial Treatment of HCV G1 2016

ARV-trial.com RUBY-I Study, cohort 2: ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV for HCV genotype 1 with renal impairment Design Open label W12.

Sofosbuvir and Ledipasvir Combination with and without Ribavirin in Patients with Hepatitis C Virus Infection; Preliminary Report of an Experience from.

C-BREEZE-2 Study: ruzasvir + uprifosbuvir for 12 weeks in genotype 1-6

Phase 2 Treatment Naïve HIV Coinfection

Chronic HCV Infection and CKD

DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?

Talking to Patients About HCV Treatment

Case 53-year-old Black Man

HCV Care in Unique Patient Populations

Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 (Ruzasvir) With or Without Ribavirin in Non-cirrhotic or Cirrhotic.

Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE

Therapeutic Background & Study Rationale

Simeprevir in HIV Coinfection, GT-1 C212 Trial

Phase 3 Treatment Naïve HIV Coinfection

Phase 2 Treatment Naïve Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE Brown A, et al. EASL 2015; Abstract P0771.

Engaging and Educating the Multidisciplinary Healthcare Team in HCV Care.

HIV : New Agents, New Strategies

Phase 3 Treatment-Naïve and Treatment-Experienced

Volume 59, Issue 4, Pages (October 2013)

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2

Phase 2b Treatment Naïve and Treatment Experienced

Elbasvir/Grazoprevir plus Sofosbuvir ± Ribavirin in Treatment-naive and Treatment-experienced Patients with Hepatitis C Virus Genotype 3 Infection and.

Advances in the Treatment of HCV Genotype 3 and HIV/HCV Coinfection

COMMIT Study: SMV + DCV in genotype 1b

Management of cirrhosis due to chronic hepatitis C

A Guideline-Based Approach to HCV Care

Phase 2 Treatment Naïve Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve HCV Genotype 1 or 3 C-SWIFT Poordad F, et al. EASL 2015; Abstract O006.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

SOF/VEL in liver transplantation with genotype 1-4 infection

What Does the Future Hold and What Will It Mean for Patients?

Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682 / Grazoprevir / MK-8408 (Ruzasvir) in Cirrhotic or Non-cirrhotic Patients with Chronic.

Survival benefits of DAA in patients with decompensated cirrhosis

Presentation transcript:

New Agents, New Regimens, New Strategies

HCV Infection and Kidney Disease

Treating HCV Infection in Patients With CKD What Are the Current Options?

RUBY-1: 3D Regimen Efficacy: 100%

RUBY-1 Safety

C-SURFER Grazoprevir/Elbasvir

C-SURFER Grazoprevir/Elbasvir

Back to the Debate Treating Patients With HCV Infection and CKD and Awaiting Kidney Transplantation

Treating HCV Infection in Patients With Advanced Liver Disease

Treating HCV Infection in Patients With ESLD Awaiting Liver Transplantation

SOLAR-1 and SOLAR-2

ALLY-1

ALLY-1: SVR12 By Child-Pugh Class Advanced Cirrhosis Cohort, All Genotypes

C-SALT Grazoprevir/Elbasvir

IMPACT Interim Analysis, Ongoing

Treating HCV Infection in Patients With Decompensated Cirrhosis

Treating HCV Infection In Patients Who Failed to Respond to Prior Treatment

OPTIMIST-1 and OPTIMIST-2 Cirrhosis + RAV = Worse Outcomes

NS5A RAVs in Patients With Compensated Cirrhosis Who Were Treated With Ledipasvir/Sofosbuvir in Phase 2 and Phase 3 Studies* (N = 511)

Development of RAVs After Treatment With All-Oral Therapies

Retreatment for Relapse After 8 or 12 Weeks of Ledipasvir/Sofosbuvir  Ribavirin

C-SALVAGE Phase 2 Study of Retreatment With Grazoprevir/ Elbasvir + Ribavirin for 12 wk After Failure to Respond to a PI-based Regimen (N = 79)

Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)